Streetbeat News

Stock Prices

CINT

CI&T (NYSE:CINT), a leader in AI-powered digital transformation, has launched CI&T/FLOW, an enterprise-grade AI platform designed to transform software and digital development workflows. The platform aims to accelerate productivity, reduce organizational complexity, and boost team performance. CI&T/FLOW is currently in private beta testing with 12 of CI&T's largest clients and plans to scale this platform across all clients in the next 12 to 24 months.

Portfolio Pulse from Happy Mohamed

July 18, 2023 | 1:02 pm

PLTR

Palantir Technologies Inc (NYSE:PLTR) shares continue to rise after hitting new 52-week highs. The surge is driven by a new partnership with SpecterOps, strong demand for its AI platform, and better-than-expected quarterly results. The company has scheduled its second-quarter financial results for Aug. 7.

Portfolio Pulse from Adam Eckert

July 18, 2023 | 1:01 pm

SQ

Over the past 3 months, 17 analysts have published their opinion on Block (NYSE:SQ) stock. The company has an average price target of $86.29, representing a 11.67% decrease from the previous average price target of $97.69. The majority of the analysts are somewhat bullish on the stock.

Portfolio Pulse from Benzinga Insights

July 18, 2023 | 1:01 pm

AIRC

Analysts have provided various ratings for Apartment Income REIT (NYSE:AIRC) within the last quarter, with 2 bullish, 1 somewhat bullish, and 1 indifferent. The average 12-month price target for AIRC is $40.75, a 0.61% decrease from the previous average price target of $41.00.

Portfolio Pulse from Benzinga Insights

July 18, 2023 | 1:01 pm

APLS

Over the past 3 months, 10 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ:APLS) stock. The analysts have an average price target of $102.4 versus the current price of Apellis Pharmaceuticals at $52.46, implying an upside. This current average has increased by 16.55% from the previous average price target of $87.86.

Portfolio Pulse from Benzinga Insights

July 18, 2023 | 1:01 pm

BBIO

Over the past 3 months, 4 analysts have published their opinion on BridgeBio Pharma (NASDAQ:BBIO) stock. The average 12-month price target for the stock is $39.5, with a high of $50.00 and a low of $29.00. This average price target has increased by 50.48% over the past month.

Portfolio Pulse from Benzinga Insights

July 18, 2023 | 1:01 pm

JBHT

J.B. Hunt Transport Services, Inc. (NASDAQ:JBHT) is expected to report lower Q2 earnings at $1.92 per share, down from $2.42 per share a year ago. The company's revenue is projected to be $3.31 billion. The company's shares rose 0.1% to close at $183.38 on Monday. Several analysts have recently adjusted their price targets for the company, with most seeing an upside of 6-9% in the stock.

Portfolio Pulse from Lisa Levin

July 18, 2023 | 1:00 pm

CE

14 analysts have provided ratings for Celanese (NYSE:CE) over the last quarter, with an average price target of $123.43, implying an upside from the current price of $121.04. The current average has decreased by 5.27% from the previous average price target of $130.30.

Portfolio Pulse from Benzinga Insights

July 18, 2023 | 1:00 pm

IMVT

Over the past 3 months, 9 analysts have published their opinion on Immunovant (NASDAQ:IMVT) stock. The average price target for the stock is $26.67, an increase of 1.29% from the previous average price target of $26.33. Out of the 9 analysts, 8 have given a bullish rating while 1 has given a somewhat bearish rating.

Portfolio Pulse from Benzinga Insights

July 18, 2023 | 1:00 pm

ASAN

CVGW

LGF-B

Insiders at Lions Gate Entertainment Corp. (LGF-B), Asana, Inc. (ASAN), and Calavo Growers, Inc. (CVGW) have recently made notable purchases of their companies' stocks. This could indicate their confidence in the companies' prospects. However, insider purchases should not be the sole indicator for making investment decisions.

Portfolio Pulse from Lisa Levin

July 18, 2023 | 12:59 pm